New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
08:53 EDTCS, IBM, UBS, AAPL, AIG, AMGN, NVS, BA, BLK, DISH, QIHU, STO, SSNLFOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Dish (DISH) to pull LightSquared bid...Lenders use social media to check borrowers' creditworthiness...A U.S.-EU trade war could break out over online privacy...Hong Kong stock exchange to rethink IPOs after Alibaba views...AIG (AIG) extends expiration of tax asset plan to 2017...REUTERS: Credit Suisse (CS) bets on a turnaround for money-losing U.S. brokerage...BlackRock (BLK), NY attorney general agreement ends analyst surveys...Apple (AAPL), Samsung (SSNLF) CEOs to attend mediation in U.S. patent fight...Boeing (BA) machinists want new vote, allege unfair labor practices...BLOOMBERG: Regulators consider Volcker exemption for smaller banks' CDOs...UBS (UBS) may spin off investment bank...As Norway loosens control, Statoil (STO) looks abroad for deals (Businessweek)...Samsung (SSNLF) sees Galaxy S5 by April, studies eye scanner...FINANCIAL TIMES: Novartis (NVS) facing criminal investigation in Japan over drug advertising...IBM (IBM) to create new $1B Watson business unit...CHINA DAILY: Qihoo 360 (QIHU) denies Alibaba interested in investing...SFGATE: Explosion reported at Amgen (AMGN).
News For DISH;AIG;CS;BLK;AAPL;SSNLF;BA;UBS;STO;NVS;IBM;QIHU;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | all recent news | >>
July 15, 2015
17:50 EDTBLKBlackRock CEO Fink expects Fed to raise rates in September
Subscribe for More Information
17:32 EDTBLKIcahn says BlackRock 'doesn't understand the risks'
Subscribe for More Information
17:24 EDTBLKBlackRock CEO Fink says ETFs create price transparency, liquidity
Larry Fink is speaking on CNBC.
17:19 EDTBLKIcahn says BlackRock a 'very dangerous company'
Subscribe for More Information
16:44 EDTBAOrbital ATK supports succesful launch of U.S. Air Force GPS satelliate
Subscribe for More Information
16:00 EDTAAPLOptions Update; July 15, 2015
Subscribe for More Information
13:57 EDTBAFAA says some Boeing 747 planes at risk of 'divergent flutter'
Subscribe for More Information
12:38 EDTAAPLGundlach says out of Apple position
Subscribe for More Information
11:01 EDTAAPLApple introduces new iPod touch, unveils new colors for iPod models
Subscribe for More Information
09:53 EDTAAPLHSBC UK says Apple Pay support coming within 2 weeks, Apple Insider says
HSBC UK (HSBC) said that Apple Pay (AAPL) support is in its final testing and availability will be coming within two weeks, reports Apple Insider. An HSBC spokesperson said, "We are excited to be one of a small number of Apple Pay launch partners. We have been working closely with Apple and are now properly reviewing and testing our systems before launching in two weeks." Reference Link
09:32 EDTAAPLActive equity options trading on open
Active equity options trading on open: AAPL FB BAC RCPT MU YUM NFLX CELG
08:35 EDTBLKCNBC to hold a conference
Subscribe for More Information
08:12 EDTIBMIBM and RTI International partner for data-driven development
Subscribe for More Information
07:58 EDTNVSAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
07:42 EDTCSCommodity Futures Trading Commission to hold a public roundtable
Subscribe for More Information
06:39 EDTAAPLApple to release new iPod touch, 9to5Mac reports
Subscribe for More Information
06:33 EDTAAPLApple 'in touch' with Iranian distributors to sell products there, WSJ reports
Subscribe for More Information
05:49 EDTBLKBlackRock reports Q2 assets under management up 3% to $4.72T
Subscribe for More Information
05:47 EDTBLKBlackRock reports Q2 operating income up 10% to $1.24B
Reports Q2 AUM growth of 3%. Reports $7.3B of long-term net outflows for Q2.
05:46 EDTBLKBlackRock reports Q2 adjusted EPS $4.96, consensus $4.80
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use